“We are assuming consistent mid-single-digit growth outside of respiratory in China.”

In context

“s and with our teams, and things are going really well for us there in terms of spec wins and orders, and, of course, sales as well. This momentum should lead to continued strength in consumables, and for equipment, we are encouraged by that momentum that we saw in the fourth quarter. We are assuming that equipment is flat for 2026, which is off of a mid-teens decline in 2025, but that is supported by our current backlog. As we think about life sciences and our discovery and medical businesses, we expect those to be flat, and we are assuming some modest improvement in our end markets there. That said, we do expect growth will improve through the year as our own comps ease, particularly in our life science consumables businesses. Lastly, we expect diagnostics to grow in a low single digit. We are assuming consistent mid-single-digit growth outside of respiratory in China. With China, we think the volume-based procurement headwinds will moderate as we move through the year. In respiratory, we have taken a look at that number again here in terms of the endemic level, and we think that's probably fairly consistent with 2025. This is how we are setting up the year based on these improving end markets and some of the momentum that we saw coming out of Q4. Now, Mike, to your point, as to upside levers, there's probably two larger drivers that are most relevant there. One is to see continued improvement across our life science end markets. We are seeing some of that. We want to see more of that, especially some of those policy headwinds that we are seeing here in the U.S. in particular. We would like to see that improved biotech funding environment fall through n”